Navigation Links
DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop
Date:8/26/2009

The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.

Horsham, PA (Vocus) August 26, 2009 -- The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.

Progression-Free Survival (PFS) endpoints are increasingly used for evaluation and approval of oncology drugs. Representatives from FDA, the National Cancer Institute (NCI), and PhRMA will present their perspectives on clinical, radiological, and statistical evaluation of progression-free survival. Sessions will include:

 
  • Clinical Assessment of Progression-Free Survival (PFS)
  • Radiological Evaluation of Progression-Free Survival (PFS)
  • Criteria for Determination of Progression
  • Statistical Evaluation of Progression-Free Survival- Role and Design of Independent Review
  • Statistical Evaluation of Progression-Free Survival--Handling Missing/Censored Observations
  • Statistical Evaluation of Progression-Free Survival--Analysis of Progression-Free Survival
  • Regulatory Considerations
Richard Pazdur, MD, Director, Office of Oncology Drug Products, CDER, FDA, will deliver the keynote address. In addition to his experience as a regulatory expert at FDA, Dr. Pazdur has distinguished himself in clinical and academic oncology. Click here for complete bio.

In addition, two tutorials will be held on October 7:

 
  • Time to Event Analysis for Non-Statisticians
  • Statistical Methods for Interval Censored Data Analyses
Click here to register for the Progression-Free Survival Oncology Workshop.

About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
+1-215-293-5812

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2796274.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
2. Advanced lung cancer patients see improved, progression-free survival
3. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
4. Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia
5. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
6. Survival differences by race most apparent in advanced stages of breast cancer
7. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Mediterranean Diet May Boost Alzheimers Survival
10. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
11. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: